Carrier effects on biological activity of amphotericin B

Clinical Microbiology Reviews

Volumn 9, Issue 4, 1996, Pages 512-531

  Brajtburg, Janina ^a   Bolard, Jacques ^b,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CNRS   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; DEOXYCHOLIC ACID; LIPID; LIPOPROTEIN;

CELL MEMBRANE; DRUG ACTIVITY; DRUG PROTEIN BINDING; DRUG STABILITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MACROPHAGE; MYCOSIS; NONHUMAN; REVIEW; THERMODYNAMICS;

ANIMALIA; MAMMALIA;

EID: 0029957682     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/cmr.9.4.512-531.1996     Document Type: Review

References (202)

1. Adler-Moore, J. P, S, M. Chiang, A. Satorîus, D. Guerra, B. McAndrews, E. J. McManus, and R. T. Proffitt. 1991. Treatment of murine candidiasis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). J. Antimicrob. Chemother. 28(Suppl. B):63-71.
2. Adler-Moore, J. P., G. Fujii, M. J. A. Lee, A. Satorius, A. Bailey, and R. Profitt. 1993. In vitro and in vivo interactions of AmBisome with pathogenic fungi. J. Liposome Res. 3:151-163.
3. Adler-Moore, J. P., and R. T. Proffitt. 1993. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of Amphotericin B. J. Liposome Res. 393:429-450.
4. Ahmad, I., A. K. Sarkar, and B. K. Bachhawat. 1989. Liposomal amphotericin B in the control of experimental aspergillosis in mice. I. Relative therapeutic efficacy of free and liposomal amphotericin B. Indian J. Biochem. Biophys. 26:351-356.
5. Ahreus, J., J. R. Graybill, P. C. Craven, and R. L. Taylor. 1984. Treatment of experimental murine candidiasis with liposome-associated amphotericin B. Sabouraudia 22:163-166.
6. Allen, S. D., K. N. Sorensen, M. J. Nejdi, C. Durant, and R. T. Profitt. 1994. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J. Antimicrob. Chemother. 34:1001-1013.
7. Allende, M. C., J. W. Lee, P. Francis, K. Garrett, H. Dollenberg, J. Berenguer, C. A. Lyman, P. A. Pizzo, and T. J. Walsh. 1994. Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrob. Agents Chemother. 38:518-522.
8. Allendorfer, R., R. R. Yates, S. H. Sun, and J. R. Graybill. 1992. Comparison of amphotericin-B lipid complex with amphotericin-B and SCH-39304 in the treatment of murine coccidioidal meningitis. J. Med. Vet. Mycol. 30:377-384
9. Amantea, M. A., R. A. Bowden, A. Forest, P. K. Working, M. S. Newman, and R. D. Mamelok. 1995. Population pharmacokinetics and renal function, sparing effects of amphotericin B in colloidal dispersion in patients receiving bone marrow transplants. Antimicrob. Agents Chemother. 39:2042-2047.
10. Annaissie, E., V. Pasternick, R. Proffitt, J. Adler-Moore, and G. P. Bodey. 1991. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur. J. Clin. Microbiol. Infect. Dis. 10:665-668.
11. Baily, G. G., and A. Nandy. 1994. Visceral leishmaniasis is more prevalent and more problematic. J. Infect. 29:241-247.
12. Bangham, A. D. 1992. Liposomes: realizing their promise. Hosp. Pract 27:51-62.
13. Barwicz, J., S. Christian, and I. Gruda. 1992. Effects of the aggregation state of amphotericin B on its toxicity to mice. Antimicrob. Agents Chemother. 36:2310-2315.
14. Barwicz, J., R. Gareau, A. Andet, A. Morisset, J. Villiard, and I. Gruda, 1991. Inhibition of the interaction between lipoproteins and amphotericin B by some delivery systems. Biochem. Biophys. Res. Commun. 181:722-728.
15. Beggs, A. W., F. A. Andrews, and G. A. Sarosi. 1978. Effects of temperature, aeration, and antioxidants on amphotericin B decay in a synthetic liquid medium, abstr. 399. In Program and Abstracts of the 18th Interscience Conference of Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
16. Belay, T., D. R. Hospenthal, A. I. Rogers, and M. J. Patterson. 1993. Treatment of systemic candidasis in a neutropenic murine model using immunoglobulin G bearing liposomal amphotericin B. Mycopathologia 123:9-17.
17. Bennet, J. E., G. J. Hill, W. T. Butier, and C. W. Emmons. 1963. Correlation of particle size of intravenous amphotericin B with toxic and chemotherapeutic effects, p. 745-752. Antimicrob. Agents Chemother, 1963.
18. Berman, J. D., W. L. Hanson, W. L. Chapman, C. R. Alving, and G. Lopez-Berestein. 1986. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob. Agents Chemother. 30:847-851.
19. Berman, J. D., G. Ksǐonski, W. L. Chapman, V. B. Waits, and W. L. Hanson. 1992. Activity of amphotericin B cholesterol dispersion (Amphocyl) in experimental visceral leishmaniasis. Antimicrob. Agents Chemother. 36:1976-1980.
20. Boggs, J. M., N. H. Chang, and A. Goundalkar. 1991. Liposomal amphotericin B inhibits in vitro T-lymphocyte response to antigen. Antimicrob. Agents Chemother. 35:879-885.
21. Bolard, J. 1986. How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochim. Biophys. Acta 864:257-304.
22. Bolard, J. 1991. Mechanism of action of an anti-candida drug: amphotericin B and its derivatives, p. 213-238. In. R. Prasad (ed.), Candida albicans. Cellular and molecular biology. Springer-Verlag KB, Berlin.
23. Bolard, J. 1991. Modulation of the immune defenses against fungi by amphotericin B and its derivatives, p. 293-305. In H. Yamaguchi, G. S. Kobayashi, and H. Takakashi (ed.), Recent progress in antifungal chemotherapy. Marcel Dekker, Inc., New York.
24. Bolard, J., and A. Andremont. 1995. Lipid formulations of amphotericin B: from clinical trials to in vitro studies, p. 397-428. In F. Puisieux, P. Couvreur, J. Delattre, and J. P. Devissaguet (ed.), Liposomes: new systems and new trends in their applications. Editions de Santé, Paris.
25. Bolard, J., and M. Chéron. 1982. Association of the polyene antibiotic amphotericin B with phospholipid vesicles. Perturbation by temperature changes. Can. J. Biochem. 60:782-789.
26. Bolard, J., M. Chéron, and J. Mazerski. 1984. Effect of surface curvature on the interaction of single lamellar phospholipid vesicles with aromatic and non aromatic heptaene antibiotics. Biochem. Pharmacol. 33:3675-3680.
27. Bolard, J., V. Joly, and P.Yeni. 1993. Mechanism of action of amphotericin B at the cellular level. Its modulation by delivery systems. J. Liposome Res. 3:409-427.
28. Bolard, J., P. Legrand, F. Heitz, and B. Cybulska. 1991. One-sided action of amphotericin B on cholesterol-containing membranes is determined by its self-association in the medium. Biochemistry 30:5707-5715.
29. Bolard, J., A. Vertut-Croquin, B. E. Cybulska, and C. M. Gary-Bobo. 1981. Transfer of the polyene antibiotic amphotericin B between single-walled vesicles of the dipalmitoyl-phosphatidylcholine and egg-yolk phosphatidylcholine. Biochim. Biophys. Acta 647:241-248.
30. Brajtburg, J., S. Elberg, J. Bolard, G. S. Kobayashi, R. A. Levy, R. E. Ostland, Jr., D. Schlessinger, and G. Medoff. 1984. Interaction of plasma proteins and lipoproteins with amphotericin B. J. Infect. Dis. 149:986-997.
31. Brajtburg, J., S. Elberg, G. S. Kobayashi, and J. Bolard. 1994. Amphotericin B incorporated into egg lecithin-bile salt mixed micelles: molecular and cellular aspects relevant to therapeutic efficacy in experimental mycoses. Antimicrob. Agents Chemother. 38:300-306.
32. Brajtburg, J., S. Elberg, G. S. Kobayashi, and G. Medoff. 1990. Inhibition of amphotericin B (Fungizone) toxicity to cells by egg lecithin-glycocholic acid mixed micelles Antimicrob. Agents Chemother. 34:2415-2416.
33. Brajtburg, J., S. Elberg, D. R. Schwartz, A. Vertut-Croquin, D. Schlessinger, G. S. Kobayashi, and G. Medoff. 1985. Involvement of oxidative damage in erythrocyte lysis induced by amphotericin B. Antimicrob. Agents Chemother. 27:172-176.
34. Brajtburg, J., S. Elberg, W. Seyfried, and J. Bolard. 1994. Influence of drug to egg lecithin ratio on the stability and therapeutic activity in mice of amphotericin B formulated with egg lecithin and bile salt, abstr. 64A2, p. 23. In Abstracts of the 94th General Meeting of the American Society for Microbiology 1994. American Society for Microbiology, Washington, D.C.
35. Brajtburg, J., S. Elberg, S. J. Travis, and G. S. Kobayashi. 1994. Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles. Antimicrob. Agents Chemother. 38:294-299.
36. Brajtburg, J., I. Gruda, I. Daigle, and G. Medoff. 1989. Concentration dependent dual effect of the monolauryl ester of sucrose on the antifungal activity and absorption spectra of amphotericin B (Fungizone). Biochim. Biophys. Acta 985:307-312.
37. Brajtburg, J., W. G. Powderly, G. S. Kobayashi, and G. Medoff. 1990. Amphotericin B: current understanding of mechanisms of action. Antimicrob. Agents Chemother. 34:183-188.
38. Caillot, D., O. Casasnovas, E. Solary, P. Chavanet, B. Bonnotte, G. Reny, F. Entezam, J. Lopez, A. Bonnin, and H. Guy. 1993. Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J. Antimicrob. Chemother. 31:161-169.
39. Caillot, D., P. Chavanet, O. Casasnovas, E. Solary, G. Zanetta, M. Buisson, O. Wagner, B. Cuisenier, A. Bonnin, P. Camerlynck, H. Portier, and H. Guy. 1992. Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B. Eur. J. Clin. Microbiol. Infect. Dis. 11:722-725.
40. Chabot, G. G., R. Pazdan, F. A. Valeriote, and L. H. Baker. 1989. Pharmacokinetics and toxicity of continuous infusion of amphotericin B in cancer patients. J. Pharm. Sci. 78:307-310.
41. Chavanet, P., N. Charlier, A. Brenet, A. Goux, E. Muggeo, D. Caillot, O. Casasnovas, J. P. Kistermann, A. Waldner, and B. Portier. 1992. Emulsion of amphotericin B in intralipid 20%: in vitro and in vivo. Pathol. Biol. 40:507-512.
42. Christansen, K. J., E. M. Bernard, J. W. M. Gold, and D. Armstrong. 1985. Distribution and activity of amphotericin B in humans. J. Infect. Dis. 152: 762-765.
43. Clark, J. M., R. R. Whitney, S. J. Olsen, R. J. George, M. R. Swerdel, L. Kunselman, and D. P. Bonner. 1991. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob. Agents Chemother. 35:615-621.
44. Clements, J. S., Jr., and J. E. Peacock, Jr. 1990. Amphotericin B revisited: reassessment of toxicity. Am. J. Med. 88:5-22N-5-27N.
45. Clemons, K. V., and D. A. Stevens. 1991. Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis. Antimicrob. Agents Chemother. 35:2144-2146.
46. Clemons, K. V., and D. A. Stevens. 1991. Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis. Antimicrob. Agents chemother. 35:1829-1833.
47. Clemons, K. V., and D. A. Stevens. 1992. Efficacies of amphotericin-B lipid complex (ABLC) and conventional amphotericin-B against murine coccidioidomycosis. J. Antimicrob. Chemother. 30:353-363.
48. Clemons, K. V., and D. A. Stevens. 1993. Therapeutic efficacy of liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis. J. Antimicrob. Chemother. 32:465-472.
49. Clemons, K. V., and D. A. Stevens. 1993. Comparison of a liposomal amphotericin formulation (AmBisome) and deoxycholate amphotericin B (Fungizone) for the treatment of murine paracoccidioidomycosis. J. Med Vet. Mycol. 31:387-394.
50. Cohen, B. E. 1987. Concentration- and time dependance of amphotericin B-induced permeability changes across ergosterol-containing liposomes. Biochim. Biophys. Acta 857:117-122.
51. Cohen, B. E. 1993. A sequential mechanism for the formation of aqueous channels by amphotericin B in liposomes. The effects of sterol and phospholipid composition. Biochim. Biophys. Acta 1108:49-58.
52. Collette, N., P. Van der Auwera, A. P. Lopez, C. Heymans, and F. Meunier. 1989. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob. Agents Chemother. 33:362-368.
53. Collette, N., P. Van der Auwera, F. Meunier, C. Lambert, J. P. Sculier, and A. Coune. 1991. Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients. J. Antimicrob. Chemother. 27:535-548.
54. Croft, S. L., R. N. Davidson, and E. A. Thornton. 1991. Liposomal amphotericin B in the treatment of visceral leishmaniasis. J. Antimicrob. Agents. 28(Suppl. B):111-118.
55. Davidson, R. N., L. Dimartino, L. Gradoni, R. Giacchino, R. Russo, G. B. Gaeta, R. Pempinello, S. Scott, F. Raimondi, A. Cascio, T. Prestileo, L. Caldeira, R. J. Wilkinson, and A. D. M. Bryceson. 1994. Liposomal amphotericin B (AmBisome) in mediterranean visceral leishmaniasis. A multicentre trial. Q. J. Med. 87:75-81.
56. Davis, S. S., C. Washington, P. West, L. Ilhum, G. Liversedge, L. Sternson, and R. Kirsh. 1987. Lipid emulsions as drug delivery systems. Ann. N. Y. Acad. Sci. 587:75-88.
57. de Marie, S., R. Janknegt, and I. A. J. Bakker-Woudenberg. 1994. Clinical use of liposomal and lipid-complexed amphotericin B. J. Antimicrob. Chemother. 33:907-916.
58. Denning, D. W. 1991. Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. J. Antimicrob. Chemother. 28(Suppl. B):1-16.
59. Dromer, F., J. Barbet, J. Bolard, J. Charreire, and P. Yeni. 1990. Improvement of amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomes. Antimicrob. Agents Chemother. 34:2055-2060.
60. 2H-NMR. Biochim. Biophys. Acta 778:435-442.
61. Edmonds, L. E., L. Davidson, and J. S. Bertino. 1989. Solubility and stability of amphotericin B in human serum. Ther. Drug Monit. 11:323-326.
62. Elberg, S., W. Seyfried, and J. Brajtburg. 1995. Effects of amphotericin B (AmB) formulated with deoxycholate (Fungizone), egg lecithin and glycocholate (Egam), or egg lecithin and deoxycholate (Edam) on survival of mice infected with Candida albicans resistant to AmB, abstr. 43A2. In Abstracts of the 95th General Meeting of the American Society for Microbiology 1995. American Society for Microbiology, Washington, D.C.
63. Emminger, W., W. Graninger, W- Emminger-Schmidmeier, A. Zoubek, K. Pillwein, M. Susani, A. Wasserer, and H. Gadner. 1994. Tolerance of high doses of amphotericin B by infusion of a liposomal formulation in children with cancer. Ann. Hematol. 68:27-31.
64. Fielding, R., A. Singer, L. Wang, S. Babbar, and L. Guo. 1992. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob. Agents Chemother. 36:299-307.
65. Fielding, R. M., P. C. Smith, L. H. Wang, J. Porter, and L. S. S. Guo. 1991. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob. Agents Chemother. 35:1208-1213.
66. Fisher, E. W., A. Toma, P. H. Fisher, and A. D. Cheesman. 1991. Rhinocerebral mucormycosis: use of liposomal amphotericin B. J. Laryngol. Otol. 105:575-577.
67. Francis P., J. W. Lee, A. Hoffman, J. Peter, A. Francesconi, J. Bacher, J. Shelhamer, P. A. Pizzo, and T. J. Walsh. 1994. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits. The potential role of bronchoalveolar d-mannitol and serum galactomannan as markers of infection. J. Infect. Dis. 169:356-358.
68. Fromtling, R. A. 1993. Amphotericin B cholesterol sulfate complex (colloidal dispersion). Drugs Future 18:303-306.
69. Fromtling, R. A. 1995. Amphotericin B lipid complex. Drugs Future 20: 129-134.
70. Gallis, H. A., R. H. Drew, and W. W. Pickard. 1990. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:308.
71. Gates, C., and R. J. Pinney. 1993. Amphotericin B and its delivery by liposomal and lipid formulation. J. Clin. Pharm. Ther. 18:147-153.
72. Gilbert, B. E., P. R. Wyde, G. Lopez-Berestein, and S. Z. Wilson. 1994. Aerosolized amphotericin B-liposomes for treatment of systemic Candida infections in mice. Antimicrob. Agents Chemother. 38:356-359.
73. Gilbert, B. E., P. R. Wyde, and S. Z. Wilson. 1992. Aerosolized liposomal amphotericin B for treatment of pulmonary and systemic cryptococcus neoformans infections in mice. Antimicrob. Agents Chemother. 36:1466-1471.
74. Glaser, V. 1995. Liposomal antifungals battle for market share. Bio/Technology 13:728-729.
75. Gokhale, P. C., R. J. Barapatre, S. H. Adavani, N. A. Kshirsagar, and S. K. Pandya. 1993. Pharmacokinetics and tolerance of liposomal amphotericin B in patients. J. Antimicrob. Chemother. 32:133-139.
76. Gokhale, P. C., R. J. Barapatre, S. H. Advani, N. A. Kshirsagar, and S. K. Pandya. 1993. Successful treatment of disseminated candidiasis resistant to amphotericin B by liposomal amphotericin B: a case report. J. Cancer Res. Clin. Oncol. 119:569-571.
77. Gondal, J. A., R. P. Swartz, and A. Rahman. 1989. Therapeutic evaluation of free liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob. Agents Chemother. 33:1544-1548.
78. Grant, C. W. M., K. S. Hamilton, K. D. Hamilton, and K. R. Barber. 1989. Physical biochemistry of a liposomal amphotericin B mixture used for patient treatment. Biochim. Biophys. Acta 984:11-20.
79. Graybill, J. R. 1994. Is there a correlation between serum antifungal concentration and clinical outcome? J. Infect. 28(Suppl. 1):17-24.
80. Graybill, J. R., and R. Bocanegra. 1995. Liposomal amphotericin B therapy of murine histoplasmosis. Antimicrob. Agents Chemother. 39:1885-1887.
81. Graybill, J. R., P. C. Craven, R. L. Taylor, D. M. Williams, and W. E. Magee. 1982. Treatment of murine cryptococcosis with liposome-associated amphotericin B. J. Infect. Dis. 145:748-752
82. Gruda, I. E., Gauthier, S. Elberg, J. Brajtburg, and G. Medoff. 1988. Effects of the detergent sucrose monolaurate on binding of amphotericin B to sterols and its toxicity for cells. Biochem. Biophys. Res. Commun. 154: 954-958.
83. Gruda, I., D. Milette, M. Brother, G. S. Kabayashi, G. Medoff, and J. Brajtburg. 1991. Structure-activity study of inhibition of amphotericin B (Fungizone) binding to sterols, toxicity to cells, and lethality to mice by esters of sucrose. Antimicrob. Agents Chemother. 35:24-28.
84. Guo, L. S. S., R. Fielding, D. D. Lasic, R. L. Hamilton, and D. Mufson. 1991. Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs. Int. J. Pharmaceutics 75:45-54.
85. Guo, L. S., and P. K. Working. 1993. Complexes of amphotericin B and cholesteryl sulfate. J. Liposome Res. 3:473-490.
86. Hamilton, K. S., K. R. Barber, J. H. Davis, K. Neal, and C. W. M. Grant. 1991. Phase behaviour of amphotericin B multilamellar vesicles. Biochim. Biophys. Acta 1062:220-226.
87. Hanson, L. H., and D. A. Stevens. 1992. Comparison of antifungal activity of amphotericin B cholesteryl sulfate colloidal dispersion. Antimicrob. Agents Chemother. 36:486-488.
88. Hartsel, S. C., C. Hatch, and W. Ayenew. 1993. How does amphotericin B work? Studies on model membrane systems. J. Liposome Res. 3:377-408.
89. Hay, R. J. 1994. Liposomal amphotericin B, AmBisome. J. Infect. 28(Suppl. 1):35-43.
90. Heymans, C., P. Van der Anwera, J. P. Sculier, A. Coune, C. Brassinne, C. Laduron, C. Hollaert, and F. Meunier. 1990. In-vitro evaluation of the antifungal activity of amphotericin B entrapped into liposomes during storage for one year. J. Antimicrob. Chemother. 25:361-366.
91. Hopfer, R. L., R., Mehta, and G. Lopez-Berestein. 1987. Synergistic antifungal activity and reduced toxicity of liposomal amphotericin B combined with gramicidin S or NF. Antimicrob. Agents Chemother. 31:1978-1981.
92. Hopfer, R. L., K. Mills, R. Mehta, G. Lopez-Berestein, V. Fainstein, and R. L. Juliano. 1984. In vitro anti fungal activities of araphotericin B and liposome-encapsulated amphotericin B. Antimicrob. Agents Chemother. 25:387-389.
93. Hospenthal, D., K. Gretzinger, and A. Rogers. 1989. Treatment of a murine model of systemic candidiasis with liposomal amphotericin B bearing antibody to Candida albicans. J. Med. Microbiol. 30:193-197.
94. Hospenthal, D. R., A. L. Rogers, and E. S. Beneke. 1989. Effect of attachment of anticandidal antibody to the surfaces of liposomes encapsulating amphotericin B in the treatment of murine candidiasis. Antimicrob. Agents Chemother. 33:16-18.
95. Hostetler, J. S., K. V. Clemons, L. H. Hanson, and D. A. Stevens. 1992. Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrob. Agents Chemother. 36:2656-2660.
96. Hughes, C. E., R. L. Bennet, and W. H. Beggs. 1987. Broth dilution testing of Candida albicans susceptibility to ketoconazole. Antimicrob. Agents Chemother. 31:643-646.
97. Janknegt, R., S. de Marie, I. A. J. M. Bakker-Woudenberg, and D. J. A. Crommelin. 1992. Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin. Pharmacokinet. 23:279-281.
98. Janoff, A. S., L. T. Boni, M. C. Popescu, S. R. Minechey, P. R. Callis, T. D. Madden, T. Taraschi, S. M. Gruner, E. Shyamsunder, M. W. Tate, R. Mendelsohn, and D. Bonner. 1988. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc. Natl. Acad. Sci. USA 85:6122-6126.
99. Janoff, A. S., W. R. Perkins, S. L. Saletan, and C. E. Swenson. 1993. Amphotericin B lipid complex (ABLC). A molecular rationale for the attenuation of amphotericin B related toxicities. J. Liposome Res. 3:451-471.
100. Joly, V., J. Bolard, L. Saint-Julien, C. Carbon, and P. Yeni. 1992. Influence of phospholipid/amphotericin B ratio and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipid-associated amphotericin B formulations. Antimicrob. Agents Chemother. 36:262-266.
101. Joly, V., J. Bolard, and P. Yeni. 1992. In vitro models for studying toxicity of antifungal agents. Antimicrob. Agents Chemother. 36:1799-1804.
102. Joly, V., R. Farinotti, L. Saint-Julien, M. Chéren, C. Carbon, and P. Yeni. 1994. In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid. Antimicrob. Agents Chemother. 38:177-183.
103. Joly, V., L. Saint-Julien, C. Carbon, and P. Yeni. 1990. Interactions of free and liposomal amphotericin B with renal proximal tubular cells in primary cultures. J. Pharmacol. Exp. Ther. 252:17-22.
104. Juliano, R. L., C. W. M. Grant, K. R. Barber, and M. A. Kalp. 1987. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Mol. Pharmacol. 31:1-11.
105. Jullien, S., and J. Bolard. 1990. La stabilité de la liaison amphotericin B-liposome détermine l'augmentation de l'index thérapeutique in vitro des formulations liposomales du médicament. Cancer Commun. 4:19-22.
106. Jullien, S., J. Brajtburg, and J. Bolard. 1990. Affinity of amphotericin B for phosphatidylcholine vesicles as a determinant of the in vitro cellular toxicity of liposomal preparations. Biochim. Biophys. Acta 1021:39-45.
107. Jullien, S., A. Contrepois, J. E. Sligh, Y. Domart, P. Yeni, J. Brajtburg, G. Medoff, and J. Bolard. 1989. Study of the effects of liposomal amphotericin B on Candida albicans, Cryptococcus neoformans and erythrocytes by using small unilamellar vesicles prepared from saturated phospholipids. Antimicrob. Agents Chemother. 33:345-349.
108. Jullien, S., A. Vertut-Croquin, J. Brajtburg, and J. Bolard. 1988. Circular dichroism for the determination of amphotericin B binding to liposomes. AnaL Biochem. 172:197-202.
109. Kan, V. L., J. E. Bennett, M. A. Amantea, M. C. Smolskis, E. McManus, D. M. Grasela, and J. W. Sherman. 1991. Comparative safety, tolerance and pharmacokinetics of amphotericin B lipid complex and amphotericin B deoxycholate in healthy male volunteers. J. Infect. Dis. 164:418-425.
110. Karyotakis, N. C., and E. J. Anaissie. 1994. Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice. Antimicrob. Agents Chemother. 38:2660-2662.
111. Kerriage, D. 1986. Mode of action of clinically important antifungal drugs. Adv. Microb. Physiol. 27:1-72.
112. Kintzel, P. E., and P. E. Kennedy. 1991. Stability of amphotericin B in 5% dextrose injection at 25 C. Am. J. Hosp. Pharm. 48:283-285.
113. Kirsh, R., R. Goldstein, J. Tarloff, D. Parris, J. Hook, N. Hanna, P. Bugelski, and G. Poste. 1988. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J. Infect. Dis. 158:1065-1070.
114. Koldin, M, H., G. S. Kobayashi, J. Brajtburg, and G. Medoff. 1985. Effects of elevation of serum cholesterol and administration of amphotericin B complexed to lipoproteins on amphotericin B-induced toxicity in rabbits. Antimicrob. Agents Chemother. 28:144-145.
115. Kotler-Brajtburg, J., G. Medoff, D. Schlessinger, and G. S. Kobayashi. 1974. Characterization of the binding of amphotericin B to Saccharomyces cerevisiae and relationship to the antifungal effects. Antimicrob. Agents Chemother. 6:770-776.
116. Krause, H. J., and R. L. Juliano. 1988. Interactions of liposome-incorporated amphotericin B with kidney epithelial cell cultures. Mol. Pharmacol. 34:286-297.
117. Lamb, K. A., C. Washington, S. S. Davis, and S. P. Denyer. 1991. Toxicity of amphotericin B emulsion to cultured canine kidney cell monolayers. J. Pharm. Pharmacol. 43:522-524.
118. Lambert, P. A., and S. M. Hammond. 1973. Potassium fluxes, first indication of membrane damage in micro-organisms. Biochem. Biophys. Res. Commun. 54:796-800.
119. Lamy-Freund, M. T., V. F. N. Ferreira, A. Faljonialario, and S. Schreier. 1993. Effect of aggregation on the kinetics of autoxidation of the polyene antibiotic amphotericin B. J. Pharm. Sci. 82:162-166.
120. Lee, J. W., M. A. Amante, P. A. Francis, E. E. Navarro, J. Bacher, P. A. Pizzo, and T. J. Walsh. 1994. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob. Agents Chemother. 38:713-718.
121. Lee, M. D., M. M. Hess, B. A. Boucher, and A. M. Apple. 1994. Stability of amphotericin B in 5% dextrose injection stored at 4 or 25°C for 120 hours. Am. J. Hosp. Pharm. 51:394-396.
122. Legrand, P., E. A. Romero, B. E. Cohen, and J. Bolard. 1992. Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes. Antimicrob. Agents Chemother. 36:2518-2522.
123. Legrand, P., A. Vertut-Doii, and J. Bolard. 1996. Comparative internalization and recycling of different amphotericin B formulations by macrophage-like cell line J774. J. Antimicrob. Chemother. 37:519-533.
124. Legrand, P., M Chéron, L. Leroy, and J. Bolard. Release of amphotericin B from delivery systems and its action against fungal and mammalian cells. J. Drug Targeting, in press.
125. Levy, R. A., R. E. Ostlund, Jr., and J. Brajtburg. 1985. The effects of amphotericin B on lipid metabolism in cultured human skin fibroblasts. In Vitro Cell. Dev. Biol. 21:26-31.
126. Lopez-Berestein, G. 1987. Liposomes as carriers of antimicrobial agents. Antimicrob. Agents Chemother. 31:675-678.
127. Lopez-Berestein, G., G. P. Bodey, L. S. Frankel, and K. Mehta. 1987. Treatment of hepatosplenic caadidiasis with liposomal-amphotericin B. J. Clin. Oncol. 5:310-317.
128. Lopez-Berestsein, G., V. Fainstein, R. Hofer, K. Mehta, M.P. Sullivan, M. Keating, M. G. Rosenblum, R. Mehta, M. Luna, E. M. Hersa, J. Reuben, R. L. Joliano, and G. P. Bodey. 1985. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer a preliminary study. J. Infect Dis. 151:704-710.
129. Lopez-Berestein, G., and J. Fidler. 1989. Treatment of systemic fungal infections with liposomal amphotericin B, p. 317-327. In G. Lopez-Berestein and J. Fidler (ed.), Liposomes in the therapy of infectious diseases and cancer. Alan R. Liss, Inc., New York.
130. Lopez-Berestein, G., R. L. Hopfer, R. Mahta, K. Mehta, E. M. Hersh, and R. L. Juliano. 1984. Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. J. Infect. Dis. 159:278-283.
131. Lopez-Berestein, G., R. L. Hopfer, R. Mehta, K. Mehta, E. M. Hersh, and R. L. Juliano. 1984. Prophylaxis of Candida albicans infection in neutropenic mice with liposome-encapsulated amphotericin B. Antimicrob. Agents Chemother. 25:366-367.
132. Lopez-Berestein, G., and R. L. Juliano. 1987. Application of liposomes to the delivery of antifungal agents, p. 253-276. In M. J. Ostro (ed.), Liposomes. Marcel Dekker, New York.
133. Lopez-Berestein, G., R. Mehta, R. Hopfer, K. Mehta, E. M. Hersh, and R. Jaliano. 1983. Effects of sterols on the therapeutic efficacy of liposomal aniphotericin B in murine candidasis. Cancer Drug Delivery 1:37-51.
134. Lopez-Berestein, G., R. Mehta, R. L. Hopfer, K. Mills, L. Kasi, K. Mehta, V. Faiastein, M. Luna, E. M. Hersh, and R. Juliano. 1983. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J. Infect Dis. 147:939-945.
135. Madden, T. D., A. S. Janoff, and P. R. Cullis. 1990. Incorporation of amphotericin B into large unilamellar vesicles composed of phosphatidylcholine and phosphatidylglycerol. Chem. Phys. Lipids 52:189-198.
136. Martin, G. P., L. M. El-Hairir, and C Marriott. 1992. Bile salt- and lysophosphatidylcholine-induced membrane damage in human erythrocytes. J. Pharm. Pharmacol. 44:646-650.
137. Mehta, R., G. Lopez-Berestein, R. Hopfer, K. Mills, and R. Juliano. 1984. Liposomal amphotericin B is toxic to fungal cells but not mammalian cells. Biochim. Biophys. Acta 77:230-234.
138. Mehta, R. T., K. Mehta, G. Lopez-Berestein, and R. L. Juliano. 1985. Effect of liposomal amphotericin B on murine macrophages and lymphocytes. Infect. Immun. 47:429-433.
139. Mehta, R. T., T. J. McQueen, A. Keyhani, and G. Lopez-Berestein. 1994. Phagocyte transport as mechanism for enhanced therapeutic activity of liposomal amphotericin B. Chemotherapy 40:256-264.
140. Meunier, F. 1994. Alternative modalities of administering amphotericin B: current issues. J. Infect. 28(Suppl. 1)51-56.
141. Meunier, F., J. P. Sculier, A. Coune, C. Brassinne, C. Heymans, C. Laduron, N. Collette, C Hollaert, D. Bron, and J. Klastersky. 1998. Amphotericin B encapsulated in liposomes administered to cancer patients. Ann. N. Y. Acad, Sci. 544:598-610.
142. Milbaud, J., M.-A. Hartmann, and J. Bolard. 1989. Interaction of the polyene antibiotic amphotericin B with model membranes; differences between small and large unilamellar vesicles. Biochimie 71:49-56.
143. Mitrano, F. P., W. R. Outman, R. J. Baptista, and J. D. Palombe. 1991. Chemical and visual stability of amphotericin B in 5% dextrose injection stored at 4°C for 35 days. Am. J. Hosp. Pharm. 48:2635-2637.
144. Mitsutake, K., S. Kohno, Y. Miyazaki, T. Noda, H. Miyazaki, T. Miyazaki, M. Kaku, H. Koga, and K. Hara. 1994. In vitro and in vivo antifungal activities of liposomal amphotericin B, and amphotericin B lipid complex. Mycopathologia 128:13-17.
145. Miyazaki, T., S. Kohno, M. Kohno, H. Koga, and K. Yamaguchi. 1990. Liposome-encapsulated amphotericin B in the treatment of experimental murine candidiasis. Tohoku J. Exp. Med. 161:273-281.
146. Moonis, M., I. Ahmad, and B. K. Bachhawat. 1994. Effect of elimination of phagocytic cells by liposomal dichlpromethylene diphosphonate on aspergillosis virulence and toxicity of amphotericin B in mice. J. Antimicrob. Chemother. 33:571-588.
147. Moreau, P., N. Milpied, N. Fayette, J. F. Ramee, and J. L. Harousseau. 1992. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with Intralipid compared with conventional amphotericin B in neutropenic patients. J. Antimicrob. Chemother. 30:535-541.
148. New, R. R., M. L. Chance, and S. Heath. 1981. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J. Antimicrob. Chemother. 8:371-381.
149. Olsen, S. J., M. R. Swrdel, B. Blue, J. N. Clark, and D. P. Bonner. 1991. Tissue distribution of amphotericin B lipid complex in laboratory animals. J. Pharm. Pharmacol. 43:831-835.
150. Pahls, S., and A Schaffner. 1994. Comparison of the activity of free and liposomal amphotericin B in vitro and in a model of systemic candidiasis and localized murine candidiasis. J. Antimicrob. Chemother. 33:73-81.
151. Patterson, T. F., P. Miniter, J. Dijkstra, F. C. Szoka, Jr., J. L. Ryan, and V. T. Andriole. 1989. Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol sulfate complexes. J. infect Dis. 159:717-724.
152. Payne, N. I., R. F. Cosgrove, A. P. Green, and L. Lin. 1987. In-vivo studies of amphotericin B liposomes derived from proliposomes: effect of formulation on toxicity and tissue disposition of the drug in mice. J. Pharm. Pharmacol. 39:22-28.
153. Perfect, J. R., and K. A. Wright. 1994. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidiasis. J. Antimicrob. Chemother. 33:73-81.
154. Perkins, W. R., S. R. Minchey, L. T. Boni, C. E. Swenson, M. C. Popescu, R. F. Pasternack, and A. S. Janoff. 1992. Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim. Biophys. Acta 1107:271-282.
155. Pfaller, M. A., M. Bale, B. Buschelman, M. Lancaster, A. Espinel-Ingroff, J. H. Rex, and M. G. Rinaldi. 1994. Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by national committee for clinical laboratory standards. Proposed standard methods. J. Clin. Microbiol. 32:1650-1653.
156. Pisarik, L., V. Joly, S. Jullien, C. Carbon, and P. Yeni. 1990. Reduction of free amphotericin B acute toxicity in mice after intravenous administration of empty liposomes. J. Infect. Dis. 161:1042-1044.
157. Powderly, W. G., G. S. Kobayashi, G. P. Herzig, and G. Medoff. 1988. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am. J. Med. 84:26-832.
158. Proffitt, R. T., A. Satorius, S. M. Chiang, L. Sullivan, and J. P. Adler-Moore. 1991. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J. Antimicrob. Chemother. 28(Suppl. B):49-61.
159. Ralph, E. D., K. R. Barber, and C. W. M. Grant. 1993. Clinical experience with multilamellar liposomal amphotericin B in patients with proven and suspected fungal infections. Scand. J. Infect. Dis. 23:487-496.
160. Ralph, E. D., A. M. Khazindar, K. R. Barber, and C. W. M. Grant 1991. Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves. Antimicrob. Agents Chemother. 35:188-191.
161. 2+ ionophore in sterol-containing liposomes. Biochim. Biophys. Acta 982:303-306.
162. Ramos, H., J. Brajtburg, V. Marques, and B. E. Cohen. 1995. Comparison of the leishmanicidal activity of Fungizone liposomal AmB and amphotericin B incorporated into egg lecithin bile salt mixed micelles. Drugs Exp. Clin. Res. 21:211-215.
163. Reuhl, K. R., M. Vapiwala, M. T. Ryzlak, and C. P. Schaffner. 1993. Comparative neurotoxicities of amphotericin B and its mono-methyl ester derivative in rats. Antimicrob. Agents Chemother. 37:419-428.
164. Ringden, O., E. Andstrom, M. Remberger, B. M. Svahn, and J. Tollemar. 1994. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplant. 14:187-192.
165. Rochelean, H., G. Saint, J. Barwicz, I. Gruda, and H.-M. Thérien. 1994. Modulation of amphotericin B activity by association with mannose ester. Immunopharmacol. Immunotoxicol. 16:419-436.
166. Saint-Julien, L., V. Joly, M. Séman, C. Carbon, and P. Yéni. 1992. Activity of MS-8209, a nonester amphotericin B derivative, in treatment of experimental systemic mycoses. Antimicrob. Agents Chemother. 36:2722-2728.
167. Sanders, S. W., K. N. Buchi, M. S. Goddard, J. K. Lang, and K. G. Tolman. 1991. Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob. Agents Chemother. 35:1029-1034.
168. Schaffner, C. P. 1987. Amphotericin B derivatives, p. 595-610. In R. A. Fromtling (ed.), Recent trends in the discovery, development and evaluation of antifungal agents. J. R. Prous, Barcelona, Spain.
169. Schindler, J. J., R. P. Warren, S. D. Allen, and M. K. Jackson. 1993. Immunological effects of amphotericin B and liposomal amphotericin B on splenocytes from immune-normal and compromised mice. Antimicrob. Agents Chemother. 37:2716-2721.
170. Schmitt, H. J., E. M. Bernard, M. Hauser, and D. Armstrong. 1988. Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Antimicrob. Agents Chemother. 32:1676-1679.
171. Sculier, J. P., C. Delcroix, C. Brassinne, C. Laduron, and C. Hollaert. 1989. Pharmacokinetics of amphotericin B in patients receiving repeated intravenous high doses of amphotericin B entrapped into sonicated liposomes. J. Liposome Res. 1:151-166.
172. Souza, L. C., R. C. Maranliao, S. Schreier, and A. Campa. 1993. In vitro and in vivo Studie of the decrease of amphotericin B toxicity upon association with triglyceride rich emulsion. J. Antimicrob. Chemother. 32:123-132.
173. Stevens, D. A. 1994. Overview of amphotericin B colloidal dispersion (Amphocil). J. Infect. 28(Suppl. 1):45-49.
174. Strauss, G. 1981. The interaction of amphotericin B with lipid bilayer vesicles. Determination of binding constants by absorption and fluorescence spectroscopy. Can. J. Spectrosc. 26:95-102.
175. Sallivan, G. W., H. T. Carper, and G. L. Mandell. 1992. Lipid complexing decreases amphotericin B inflammatory activation of human neutrophils compared with that of a deoxycholate-suspended preparation of amphotericin B (Fungizone). Antimicrob. Agents Chemother. 36:39-45.
176. Surarit, R., and M. G. Shepherd. 1987. The effects of azole and polyene antifungals on the plasma membrane enzymes of Candida albicans. J. Med. Vet. Mycol. 25:403-109.
177. Szoka, F. C., D. Milholland, and M. Barza. 1987. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposomal-intercalated amphotericin B. Antimicrob. Agents Chemother. 31:421-429.
178. Tancrede, P., J. Barwicz, S. Jutras, and I. Gruda. 1990. The effect of surfactants on the aggregation state of amphotericin B. Biochim. Biophys. Acta 1034:289-295.
179. Tasset, C., F. Goethals, V. Préat, and M. Roland. 1989. Effect of polyoxy-ethyleneglycol (24) cholesterol on the solubility, toxicity and activity of amphotericin B. Int. J. Pharm. 58:41-48.
180. Tasset, C., V. Préat, and M. Roland. 1991. The influence of Myrj 59 on the solubility, toxicity and activity of amphotericin B. J. Pharm. Pharmacol. 43:297-302.
181. Tasset, C., V. Préat, and M. Roland. 1992. Formulations galéniques d'amphotéricine B. J. Pharm. Belg. 47:523-536.
182. Taylor, A. W., B. J. Cestello, P. A. Hunter, W. S. Maclanand, and C. T. Shanks. 1993. Synthesis and antifungal selectivity of new derivatives of amphotericin B modified at the C,13 position. J. Antibiot. 46:486-493.
183. Taylor, R. L., D. M. Williams, P. C. Craven, J. R. Graybil, D. J. Drutz, and W. E. Magee. 1982. Amphotericin B in liposomes: a novel therapy for histoplasmosis. Annu. Rev. Respir. Dis. 125:610-611.
184. Tollemar, J., R. Duraj, and B. G. Ericzon. 1990. Liposomal amphotericin B treatment in a 9-month-old liver recipient. Mycoses 33:251-252.
185. Tremblay, C., M. Barza, C. Fiore, and F. Szoka. 1984. Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob. Agents Chemother. 26:170-173.
186. Valero, G., and J. R. Graybill. 1995. Successful treatment of cryptococcal meningitis with amphotericin B colloidal dispersion: report of four cases. Antímicrob. Agents Chemother. 39:2588-2590.
187. van Etten, E. W. M., M. T. ten Kate, L. E. T. Stearn, and I. A. J. M. Bakker-Woudenberg. 1995. Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leucopenic mice. Antimicrob. Agents Chemother. 39: 1954-1958.
188. Van Etten, E. W. M., C. van den Heuvel-de Groot, and I. A. J. M. Bakker-Woudenberg. 1993. Efficacies of amphotericin B-deoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immanocompetent and leucopenic mice. J. Antimicrob. Chemother. 32:723-739.
189. Vecchiarelli, A., G. Verducci, & Perito, P. Pucetti, P. Marconi, and F. Bistoni. 1986. Involvment of host macrophages in the immunoadjuvant activity of amphotericin B in a mouse fungal infection model. J. Antibiot 39:846-850.
190. Vertut-Croquin, A., J. Bolard, and C. Gary-Bobo. 1984. Enhancement of amphotericin B selectivity by antibiotic incorporation into gel state vesicles. A circular dichroism and permeability study. Biochem. Biophys. Res. Commun. 125:360-365.
191. Vertut-Croquin, A., J. Bolard, and C. Gary-Bobo. 1985. Transfer of amphotericin B from gel state vesicles to Mycoplasma cells: biphasic action on potassium transport and permeability. Antimicrob. Agents Chemotber. 28: 167-171.
192. + pump of human erythrocytes. Biochem. Biophys. Res. Commun. 157:692-697.
193. Vertut-Doi, A., S. Ohnishi, and J. Bolard. 1994. The endocytic process in CHO cells, a toxic pathway of the polyene antibiotic amphotericin B. Antimicrob. Agents Chemother. 38:2373-2379.
194. Viviani, M. A., Rizzardini, G., A. M. Tortorano, M. Fasan, A. Capetti, A. M. Roverselli, A. Gringeri, and F. Suter. 1994. Lipid based amphotericin B in the treatment of cryptococcoses. Infection 22:137-142.
195. Vyyoda, O. S., R. Coleman, and G. Holdsworth. 1977. Effects of different bile salts upon the composition and morphology of a liver plasma membrane preparation. Deoxycholate is more membrane damaging than cholate and its conjugates. Biochim. Biophys. Acta 465:68-76.
196. Wang, L. H., R. M. Fielding, P. C. Smith, and L. S. S. Guo. 1995. Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (Amphocil) and Fungizone after repeated dosing in rats. Pharm. Res. 12:275-283.
197. Wasan, K. M., G. A. Brazeau, A. Keyhani, A. C Hayman, and G. Lopez-Berestein. 1993. Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrob. Agents Chemother. 37:246-250.
198. Wasan, K. M., and G. Lopez-Berestein. 1993. The influence of serum lipoproteins on the pharmacokinetics and pharmacodynamics of lipophilic drugs and drug carriers. Arch. Med. Res. 24:395-401.
199. Wasan, K. M., R. E. Morton, M. G. Rosenblum, and G. Lopez-Berestein. 1994. Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein. J. Pharm. Sci. 83:1006-1010.
200. Wasan, K. M., K. Vadlei, G. Lopez-Berestein, and D. R. Luke. 1990. Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. J. Infect. Dis. 161:562-566.
201. Washington, C., M. Lance, and S. S. Davis. 1993. Toxicity of amphotericin B emulsion formulations. J. Antimicrob. Chemother. 31:806-808.
202. Yamaguchi, H., S. Abe, and Y. Tokuda. 1993. Immunomodulating activaty of antifungal drugs. Ann. N. Y. Acad. Sci. 685:447-457.